A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.

@article{Sutherland1997ARP,
  title={A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.},
  author={Lloyd R. Sutherland and François Martin and Robert J. Bailey and Richard N Fedorak and M H Poleski and Chrystian Dallaire and Roni Rossman and Fred G Saibil and Lyne Larivi{\`e}re},
  journal={Gastroenterology},
  year={1997},
  volume={112 4},
  pages={1069-77}
}
BACKGROUND & AIMS The efficacy of mesalamine for the maintenance of remission in patients with Crohn's disease is controversial. The aim of this study was to conduct a double-blind, placebo-controlled study of mesalamine (750 mg four times a day for 48 weeks) in maintaining remission in 293 patients with Crohn's disease. Patients were stratified according to the method of induction of remission (medical or surgical). METHODS Patients were assessed at weeks 4, 12, 24, 36, and 48. Relapse was… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…